碲化铋前药纳米平台用于光热协同化疗抗肿瘤  

A Bismuth Telluride-Based Prodrug Nano-Platform is Utilized for Photo-Thermal Synergistic Chemo-Therapy Against Tumors

作　　者：傅晨晨 仇萌 Fu Chenchen;Qiu Meng(College of Chemistry and Chemical Engineering,Ocean University of China,Qingdao 266100,China)

机构地区：[1]中国海洋大学化学化工学院,山东青岛266100

出　　处：《中国海洋大学学报(自然科学版)》2025年第5期118-127,共10页Periodical of Ocean University of China

基　　金：中央高校基础科研专项项目(202341006)资助。

摘　　要：开发高效低毒的抗肿瘤药物是生物医学研究的重要目标之一。本文通过溶剂热法制备了牛血清白蛋白(BSA)修饰的碲化铋纳米片(Bi_(2)Te_(3)-BSA NSs),显著提高了碲的稳定性和生物安全性。Bi_(2)Te_(3)-BSA NSs具有良好的光热转化能力,可对肿瘤细胞进行有效杀伤。同时Bi_(2)Te_(3)-BSA NSs降解生成的Te(Ⅳ)可破坏线粒体膜电位,促进细胞凋亡。体外研究表明,Bi_(2)Te_(3)-BSA NSs光热协同化疗治疗后,MCF-7细胞的存活率仅为2.3%,表现出良好的抗肿瘤潜力。本研究为无机纳米前药平台用于光热协同化疗抗肿瘤提供了一种新策略,有望用于肿瘤治疗领域。One of the important goals of biomedical research is to develop highly efficient and low-toxicity anti-tumor drugs.In this study,bovine serum albumin(BSA)-modified bismuth telluride nanosheets(Bi_(2)Te_(3)-BSA NSs)were prepared via a solvothermal method,significantly enhancing the stability and biocompatibility of tellurium.Bi_(2)Te_(3)-BSA NSs exhibit excellent photothermal conversion capability,effectively killing tumor cells.At the same time,the degradation product Te(Ⅳ)of Bi_(2)Te_(3)-BSA NSs can disrupt mitochondrial membrane potential and promote cell apoptosis.In vitro studies have shown that after photothermal synergistic chemotherapy treatment with Bi_(2)Te_(3)-BSA NSs,the survival rate of MCF-7 cells was only 2.3%,demonstrating promising anti-tumor potential.This study provides a new strategy for the use of inorganic nano-prodrug platforms for photothermal synergistic chemotherapy against tumors and holds promise for the field of cancer treatment.

关 键 词：Bi_(2)Te_(3)前药平台 光热 化疗 线粒体功能障碍 抗肿瘤 

分 类 号：R318.08[医药卫生—生物医学工程]